Drugs

Article	Citations
Correction: New Pharmacologic Approaches to the Treatment of Bipolar Depression	429
Comment on “Recent Human Papillomavirus Vaccination is Associated with a Lower Risk of COVID-19: A US Database Cohort Study”	415
Correction: Targeting KRASG12C in Non-Small-Cell Lung Cancer: Current Standards and Developments	302
Bimekizumab for the Treatment of Psoriasis	294
Authors’ Reply to Toda: Multimodal Multidisciplinary Management of Patients with Moderate to Severe Pain in Knee Osteoarthritis: A Need to Meet Patient Expectations	220
Targeting DNA Damage Response Deficiency in Thoracic Cancers	191
Suprachoroidal Space Triamcinolone Acetonide: A Review in Uveitic Macular Edema	176
Alcohol-Associated Liver Disease: Evolving Concepts and Treatments	162
Analysis of Cerebrospinal Fluid, Plasma β-Amyloid Biomarkers, and Cognition from a 2-Year Phase 2 Trial Evaluating Oral ALZ-801/Valiltramiprosate in APOE4 Carriers with Early Alzheimer’s Disease Using	146
Eftrenonacog Alfa: A Review in Haemophilia B	123
Epcoritamab: First Approval	119
Vorasidenib: First Approval	118
Spesolimab for the Treatment of Generalized Pustular Psoriasis	115
Aprocitentan: First Approval	111
Teclistamab: First Approval	109
New Therapies on the Horizon for Primary Biliary Cholangitis	107
Asthma and Cardiovascular Diseases: Navigating Mutual Pharmacological Interferences	103
Cosibelimab: First Approval	102
Upacicalcet: First Approval	102
Drugs in Development to Manage Acute Pain	101
Efficacy and Safety of CDK4/6 Inhibitors: A Focus on HR+/HER2− Early Breast Cancer	97
Olipudase Alfa: First Approval	97
Safety of Anti-osteoarthritis Medications: A Systematic Literature Review of Post-marketing Surveillance Studies	97
Influenza Vaccine Effectiveness and Progress Towards a Universal Influenza Vaccine	93
Emerging Therapies for Chronic Hepatitis B and the Potential for a Functional Cure	92

Dostarlimab: First Approval	91
Repotrectinib: First Approval	88
Danicopan: First Approval	88
Finerenone: First Approval	88
Atogepant: First Approval	87
QT Prolongation and Risk of Death with the Use of Methadone for Chronic Cancer and Noncancer Pain: Myths or Reality?	85
Androgenetic Alopecia: Therapy Update	85
Lenacapavir: First Approval	83
Novel Drugs for the Treatment of Pulmonary Arterial Hypertension: Where Are We Going?	83
Correction to: Ofatumumab: A Review in Relapsing Forms of Multiple Sclerosis	81
Olverembatinib: First Approval	79
SER-109 (VOWST™): A Review in the Prevention of Recurrent Clostridioides difficile Infection	78
Mosunetuzumab: First Approval	78
Relugolix/Estradiol/Norethisterone (Norethindrone) Acetate: A Review in Symptomatic Uterine Fibroids	77
Cancer Pain Treatment Strategies in Patients with Cancer	75
Treatment of Cryptococcal Meningitis: How Have We Got Here and Where are We Going?	75
Alzheimer’s Disease: Novel Targets and Investigational Drugs for Disease Modification	75
Correction to: Cefiderocol: A Review in Serious Gram-Negative Bacterial Infections	74
Aligning Large Language Models with Humans: A Comprehensive Survey of ChatGPT’s Aptitude in Pharmacology	72
Correction to: Fenfluramine: A Review in Dravet and Lennox-Gastaut Syndromes	72
Correction to: Tapinarof Cream 1%: First Approval	72
PARP Inhibition, a New Therapeutic Avenue in Patients with Prostate Cancer	71
Drugs Targeting Cough Receptors: New Therapeutic Options in Refractory or Unexplained Chronic Cough	69
Pharmacological Treatments of Temporomandibular Disorders: A Systematic Review Including a Network Meta-Analysis	69
Sunvozertinib: First Approval	69
Correction to: Prevention and Treatment of Monkeypox	69
Dorzagliatin: First Approval	68
Targeting Interferon Signalling in Systemic Lupus Erythematosus: Lessons Learned	68
Overview of DaxibotulinumtoxinA for Injection: A Novel Formulation of Botulinum Toxin Type A	67
The Place of Cannabinoids in the Treatment of Gynecological Pain	67
Tovorafenib: First Approval	65
Pozelimab: First Approval	64
Treatment of Ovarian Cancer Beyond PARP Inhibition: Current and Future Options	64
The Utilization of the Accelerated Approval Pathway in Oncology: A Case Study of Pembrolizumab	63
Correction to: Targeting Sphingosine-1-Phosphate Signaling in Immune-Mediated Diseases: Beyond Multiple Sclerosis	62
Correction to: Concizumab: First Approval	62
Current Management of Peripheral Artery Disease: Focus on Pharmacotherapy	62
Recent Human Papillomavirus Vaccination is Associated with a Lower Risk of COVID-19: A US Database Cohort Study	61
Focus on Metformin: Its Role and Safety in Pregnancy and Beyond	61
Correction to: Remdesivir: A Review in COVID-19	61
Correction: From Prospective Evaluation to Practice: Model-Informed Dose Optimization in Oncology	61
Tirzepatide: A Review in Type 2 Diabetes	59
Might It Be Appropriate to Anticipate the Use of Long-Acting Muscarinic Antagonists in Asthma?	59
Disitamab Vedotin: First Approval	58
Pharmacotherapy for Dravet Syndrome: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials	58
Gepirone Extended-Release: First Approval	58
Effects of Oral ALZ-801/Valiltramiprosate on Plasma Biomarkers, Brain Hippocampal Volume, and Cognition: Results of 2-Year Single-Arm, Open-Label, Phase 2 Trial in APOE4 Carriers with Early Alzheimer’	56
Birch Bark Extract: A Review in Epidermolysis Bullosa	55
Aumolertinib: A Review in Non-Small Cell Lung Cancer	54
Asciminib: First Approval	53

Catumaxomab: First Approval	53
Fluvoxamine for the Early Treatment of SARS-CoV-2 Infection: A Review of Current Evidence	53
Givinostat: First Approval	52
Paracetamol Combination Therapy for Back Pain and Osteoarthritis: A Systematic Review and Meta-Analyses	51
Ozoralizumab: First Approval	51
Correction to: Efmoroctocog Alfa: A Review in Haemophilia A	50
Correction: Teprotumumab: A Review in Thyroid Eye Disease	50
Mitapivat: A Review in Pyruvate Kinase Deficiency in Adults	50
Correction to: Sotorasib: First Approval	50
Ensitrelvir Fumaric Acid: First Approval	49
Current Understanding of Complement Proteins as Therapeutic Targets for the Treatment of Immunoglobulin A Nephropathy	49
Omalizumab in Severe Asthma: Effect on Oral Corticosteroid Exposure and Remodeling. A Randomized Open-Label Parallel Study	48
Avacincaptad Pegol: First Approval	48
Fezolinetant: First Approval	48
Tisotumab Vedotin: First Approval	47
Futibatinib: First Approval	47
Update on Mpox Management: Epidemiology, Vaccines and Therapeutics, and Regulatory Changes	47
Treatment of Non-Infectious Corneal Injury: Review of Diagnostic Agents, Therapeutic Medications, and Future Targets	47
Spondyloarthropathy in Inflammatory Bowel Disease: From Pathophysiology to Pharmacological Targets	46
Zastaprazan: First Approval	46
Advanced-Stage Chronic Myeloid Leukemia: Options for Difficult Treatment Situations	46
Effectiveness of Interventions to Reduce Opioid Use After Orthopaedic Surgery: A Systematic Review of Randomised Controlled Trials	45
Eye Involvement and Management in Inherited Epidermolysis Bullosa	45
Correction: Lumasiran: A Review in Primary Hyperoxaluria Type 1	44
Daratumumab: A Review in Newly Diagnosed Systemic Light Chain Amyloidosis	44
Correction: Iptacopan: First Approval	44
Could Sodium/Glucose Co-Transporter-2 Inhibitors Have Antiarrhythmic Potential in Atrial Fibrillation? Literature Review and Future Considerations	44
Imeglimin Hydrochloride: First Approval	43
The Antifungal Pipeline: Fosmanogepix, Ibrexafungerp, Olorofim, Opelconazole, and Rezafungin	42
Imetelstat: First Approval	42
Lotilaner Ophthalmic Solution 0.25%: First Approval	42
Varenicline Solution Nasal Spray: A Review in Dry Eye Disease	41
Beremagene Geperpavec: First Approval	41
Recent United States Developments in the Pharmacological Treatment of Dry Eye Disease	40
Global Consumption Trend of Antifungal Agents in Humans From 2008 to 2018: Data From 65 Middle- and High-Income Countries	40
Savolitinib: First Approval	40
Tamoxifen Dose De-Escalation: An Effective Strategy for Reducing Adverse Effects?	40
Safety of Janus Kinase Inhibitors in Inflammatory Bowel Diseases	39
Targeting the Sphingosine-1-Phosphate Pathway: New Opportunities in Inflammatory Bowel Disease Management	39
Gastrointestinal Dysfunction in Parkinson’s Disease	39
Tebentafusp: First Approval	39
Acknowledgement to Referees	39
Remdesivir Discontinuation Decisions Based on Thresholds of Aminotransferase in an Observational Registry	37
Correction to: Pharmacological Approaches to Managing Violence and Aggression in Prison Populations: Clinical and Ethical Issues	37
Crinecerfont: First Approval	36
Botulinum Toxin-A for the Treatment of Myogenous Temporomandibular Disorders: An Umbrella Review of Systematic Reviews	36
Mavorixafor: First Approval	36
Revolutionary Changes in the Management of Lupus Nephritis: Towards De-Glucocorticoid or No-Glucocorticoid	36
Immune Mechanisms in Epileptogenesis: Update on Diagnosis and Treatment of Autoimmune Epilepsy Syndromes	35
Efficiency and Safety of Noninvasive and Intravesical Therapy for Adult Neurogenic Lower Urinary Tract Dysfunction: A Systematic Review and Network Meta-analysis of Randomized Controlled Trials	35
Authors’ Reply to Mazza et al.: “Fluvoxamine for the Early Treatment of SARS‑CoV‑2 Infection: A Review of Current Evidence”	35
Avatrombopag: A Review in Thrombocytopenia	34
Retifanlimab: First Approval	34
Epidemiology, Treatments, and Vaccine Development for Antimicrobial-Resistant Neisseria gonorrhoeae: Current Strategies and Future Directions	33
Nogapendekin alfa Inbakicept: First Approval	33
Revumenib: First Approval	33
Donafenib: First Approval	33
Diagnosis and Treatment of AL Amyloidosis	32
The Epidemiology and Pathogenesis and Treatment of Pseudomonas aeruginosa Infections: An Update	32
Combination of PARP Inhibitors and Androgen Receptor Pathway Inhibitors in Metastatic Castration-Resistant Prostate Cancer	31
Correction to: Abrocitinib: First Approval	31
Moderate-Intensity Statin Plus Ezetimibe: Time to Rethink it as an Optimal Initial Lipid-Lowering Strategy	31
Correction to: Sparsentan: First Approval	31
Evolution of Type 2 Diabetes Management from a Glucocentric Approach to Cardio-Renal Risk Reduction: The New Paradigm of Care	30
Correction to: REal worlD Effectiveness and Safety of Mepolizumab in a Multicentric Spanish Cohort of Asthma Patients Stratified by Eosinophils: The REDES Study	30
Rationale and Clinical Use of Bronchodilators in Adults with Bronchiectasis	30
Keverprazan Hydrochloride: First Approval	30
Direct-Acting Antivirals and the Risk of Arrhythmias and Conduction Disorders in Patients with Chronic Hepatitis C: A French Nationwide Cohort Study	30
Recent Clinical Trials Insights into the Treatment of Primary Membranous Nephropathy	30
Correction: Zastaprazan: First Approval	30
Efficacy and Safety of Sovateltide in Patients with Acute Cerebral Ischaemic Stroke: A Randomised, Double-Blind, Placebo-Controlled, Multicentre, Phase III Clinical Trial	30
Insights Into the Results of Sotagliflozin Cardiovascular Outcome Trials: Is Dual Inhibition the Cherry on the Cake of Cardiorenal Protection?	29
Gabapentinoids for Pain: A Review of Published Comparative Effectiveness Trials and Data Submitted to the FDA for Approval	29
Comment on: “Risk of Erectile Dysfunction in Male Patients with Gout Treated with Febuxostat or Allopurinol: A Propensity Score-Matched Cohort Study”	29
Zolbetuximab: First Approval	28
Correction to: Spesolimab: First Approval	28
Ravulizumab: A Review in Generalised Myasthenia Gravis	28
Methadone for Cancer Pain Management in Children: A Review of Literature	28
Safety, Immunogenicity and Interchangeability of Biosimilar Monoclonal Antibodies and Fusion Proteins: A Regulatory Perspective	28
Daridorexant: First Approval	28

Antibacterials with Novel Chemical Scaffolds in Clinical Development	28
Remdesivir: A Review in COVID-19	27
Ripretinib: A Review in Gastrointestinal Stromal Tumours as Fourth-or Later-Line of Therapy	27
Tapentadol Versus Tramadol: A Narrative and Comparative Review of Their Pharmacological, Efficacy and Safety Profiles in Adult Patients	27
Odevixibat: First Approval	26
Refractory Systemic Lupus Erythematosus: Identification and Pharmacological Management	26
Regdanvimab: First Approval	26
Novel Drug Therapeutics in Celiac Disease: A Pipeline Review	26
Hyperkalemia in Chronic Kidney Disease in the New Era of Kidney Protection Therapies	25
Molnupiravir: First Approval	25
Publisher Correction: Efficacy and Safety of RBX2660 in PUNCH CD3, a Phase III, Randomized, Double-Blind, Placebo-Controlled Trial with a Bayesian Primary Analysis for the Prevention of Recurrent Clos	25
Marstacimab: First Approval	25
Nadofaragene Firadenovec: First Approval	25
Treatment of Osteoporosis and Osteoarthritis in the Oldest Old	25
Gefapixant: First Approval	25
Abrocitinib: First Approval	25
Correction to: Mavacamten: First Approval	24
Correction to: Rozanolixizumab: First Approval	24
Elranatamab: First Approval	24
Pucotenlimab: First Approval	24
Comment on: “Managing Diabetic Foot Ulcers: Pharmacotherapy for Wound Healing”	24
Lecanemab: First Approval	24
Association of Metformin with the Mortality and Incidence of Cardiovascular Events in Patients with Pre-existing Cardiovascular Diseases	24
Tixagevimab + Cilgavimab: First Approval	24
Amubarvimab/Romlusevimab: First Approval	24
Ofatumumab: A Review in Relapsing Forms of Multiple Sclerosis	24
Spesolimab: First Approval	24
A Review of RRx-001: A Late-Stage Multi-Indication Inhibitor of NLRP3 Activation and Chronic Inflammation	24
Tofersen: First Approval	23
Ritlecitinib: First Approval	23
Chiglitazar: First Approval	23
Correction to: Contezolid: First Approval	23
Renal Safety Assessment of Lipid-Lowering Drugs: Between Old Certainties and New Questions	23
New Developments in Glucagon Treatment for Hypoglycemia	22
Sirtuins and Cellular Senescence in Patients with Idiopathic Pulmonary Fibrosis and Systemic Autoimmune Disorders	22
Talquetamab: First Approval	22
Comment on “Trientine Tetrahydrochloride, From Bench to Bedside: A Narrative Review”	22
Correction to: Ozanimod: A Review in Ulcerative Colitis	22
Furmonertinib: First Approval	22
Comment on: ‘Should We Interfere with the Interleukin-6 Receptor During COVID-19: What Do We Know?’	22
Acknowledgement to Referees	22
Chronic Obstructive Pulmonary Disease (COPD): Developments in Pharmacological Treatments	22
Elafibranor: First Approval	21
Risk of COVID-19 Diagnosis and Hospitalisation in Patients with Osteoarthritis or Back Pain Treated with Ibuprofen Compared to Other NSAIDs or Paracetamol: A Network Cohort Study	21
Optimized Dosing: The Next Step in Precision Medicine in Non-Small-Cell Lung Cancer	21
Treatment Approaches for Carbapenem-Resistant Acinetobacter baumannii Infections	21
Valoctocogene Roxaparvovec: First Approval	21
Targeted Small Molecules for Systemic Lupus Erythematosus: Drugs in the Pipeline	21
Drug Survival of IL-17 and IL-23 Inhibitors for Psoriasis: A Systematic Review and Meta-Analysis	21
Eplontersen: First Approval	21
Differentiating IL-23 Inhibitors in Crohn’s Disease	21
Dimdazenil: First Approval	21
A Meta-analysis Exploring the Efficacy of Neuropathic Pain Medication for Low Back Pain or Spine-Related Leg Pain: Is Efficacy Dependent on the Presence of Neuropathic Pain?	20
First-line Immune Checkpoint Inhibitor Combinations in Metastatic Renal Cell Carcinoma: Where Are We Going, Where Have We Been?	20
Tunlametinib: First Approval	20
20-Valent Pneumococcal Conjugate Vaccine: A Review of Its Use in Adults	20
Iptacopan: First Approval	20
How Psychedelics Modulate Multiple Memory Mechanisms in Posttraumatic Stress Disorder	20
Motixafortide: First Approval	20
Inhaled Phosphodiesterase Inhibitors for the Treatment of Chronic Obstructive Pulmonary Disease	19
PI3K Inhibitors as Potential Therapeutic Agents for the Treatment of COPD with Associated Atherosclerosis	19
TKI Treatment Sequencing in Advanced Gastrointestinal Stromal Tumors	19
Vosoritide: First Approval	19
Association of Glucagon-Like Peptide-1 Receptor Agonist with Progression to Liver Cirrhosis and Alcohol-Related Admissions in Patients with Alcohol Use Disorder and Diabetes: A Retrospective Cohort St	19
Tirzepatide: First Approval	18
Exploring Novel Pharmacotherapy Candidates for Cannabis Use Disorder: Uncovering Promising Agents on the Horizon by Mechanism of Action	18
Sulbactam/Durlobactam: First Approval	18
Intraperitoneal Chemotherapy for Unresectable Peritoneal Surface Malignancies	18
Sotorasib: First Approval	17
Authors’ Reply to Colak et al.: “Managing Diabetic Foot Ulcers: Pharmacotherapy for Wound Healing”	17
Immune Checkpoint Inhibition for Unresectable Malignant Pleural Mesothelioma	17
Tegileridine: First Approval	17
Vimseltinib: First Approval	17
Vamorolone: First Approval	17
Use of Levosimendan in Patients with Pulmonary Hypertension: What is the Current Evidence?	17
Postpartum Depression: A Clinical Review of Impact and Current Treatment Solutions	17
Vutrisiran: A Review in Polyneuropathy of Hereditary Transthyretin-Mediated Amyloidosis	17
Mirvetuximab Soravtansine: First Approval	17
Overall and Sex-Specific Effect of Berberine for the Treatment of Dyslipidemia in Adults: A Systematic Review and Meta-Analysis of Randomized Placebo-Controlled Trials	17
Drugs in Development to Treat IgA Nephropathy	17
Treatment Options in Spinal Muscular Atrophy: A Pragmatic Approach for Clinicians	17
Cabotegravir Extended-Release Injectable Suspension: A Review in HIV-1 Pre-Exposure Prophylaxis	16
A Multicentric, Randomized, Controlled Phase III Study of Centhaquine (Lyfaquin®) as a Resuscitative Agent in Hypovolemic Shock Patients	16
Chinese Herbal Medicines for Coronary Heart Disease: Clinical Evidence, Pharmacological Mechanisms, and the Interaction with Gut Microbiota	16
Linzagolix: First Approval	16
Nemolizumab: First Approval	16
Drug-Induced Pigmentation: A Review	16
Results from Expanded Access Programs: A Review of Academic Literature	16
BCMA-Targeted Biologic Therapies: The Next Standard of Care in Multiple Myeloma Therapy	16
Managing Psoriatic Arthritis Patients Presenting with Axial Symptoms	15
Anticoagulation in Chronic Kidney Disease	15
Fenfluramine: A Review in Dravet and Lennox-Gastaut Syndromes	15
Current and Emerging Therapies for Lysosomal Storage Disorders	15
Pharmacologic Management of Persistent Pain in Cancer Survivors	15
The Potential of RNA Therapeutics in Treating Cardiovascular Disease	15